The correlation between serum levels of Hcy, blood lipid and cognitive disorder in patients with chronic schizophrenia

doi:10.3969/j.issn.1673-8640.2015.12.008

Abstract

Abstract:

Objective To determine serum homocysteine(Hcy)and blood lipid, and to investigate the relationships of Hcy and blood lipid with cognitive function in patients with chronic schizophrenia.Methods The levels of Hcy, total cholesterol(TC), triglyceride (TG), high-density lipoprotein cholesterol(HDL-C) and low-density lipoprotein cholesterol(LDL-C)were determined in 154 patients with chronic schizophrenia and 60 healthy subjects(healthy control group). The patients with chronic schizophrenia were classified into cognitive impairment group and non-cognitive impairment group according to the assessment of Montreal Cognitive Assessment (MoCA). The results were analyzed statistically. Results In cognitive impairment group, the levels of Hcy, TC, TG and LDL-C were significantly higher than those in non-cognitive impairment group and healthy control group(P<0.05), and the level of HDL-C was lower than that in healthy control group(P<0.05).Univariate Logistic regression analysis showed that Hcy,TC,TG and LDL-C were risk factors for cognitive impairment in patients with chronic schizophrenia [odds ratios(OR)were 1.114, 1.791, 2.141 and 1.556; 95% confidence intervals(CI)were 1.034-1.200, 1.237-2.593, 1.263-3.630 and 1.091-2.217]. Multivariate Logistic regression analysis showed that only Hcy was an independent risk factor for cognitive impairment in patients with chronic schizophrenia(OR=1.125, 95%CI was 1.040-1.217). Serum Hcy had negative correlation with MoCA score in patients with chronic schizophrenia(r=-0.362, P=0.000). Conclusions Cognitive impairment in patients with chronic schizophrenia may be associated with abnormal metabolism of Hcy and blood lipid.

Key words: Homocysteine, Blood lipid, Schizophrenia, Cognition, Montreal Cognitive Assessment

CLC Number:

R446.1

WANG Xiaoyan, WANG Weiling, DING Binbin, CHEN Shurong, ZHANG Suqin, ZHU Guang, LUO Biming, WANG Zuowei. The correlation between serum levels of Hcy, blood lipid and cognitive disorder in patients with chronic schizophrenia[J]. Laboratory Medicine, 2015, 30(12): 1198-1202.

Figures/Tables 4

References 16

[1]	HOOSHMAND B,SOLOMON A,KAREHOLT I,et al.Homocysteine and holotranscobalamin and the risk of Alzheimer disease:a longitudinal study[J].Neurology,2010,75(16):1408-1414.
[2]	SONG IU,KIM JS,PARK IS,et al.Clinical significance of homocysteine(hcy) on dementia in Parkinson's disease(PD)[J]. Arch Gerontol Geriatr,2013,57(3):288-291.
[3]	AMANO T,HOSAKA S,TAKAMI H,et al.The lipid metabolism abnormality in patients administered with olanzapine[J]. Nihon Shinkei Seishin Yakurigaku Zasshi,2012,32(5-6):257-261.
[4]	TANIOKA T,FUJI S,KATAOKA M,et al.Retrospective study of Japanese patients with schizophrenia treated with aripiprazole[J]. ISRN Nurs,2012,2012:454898.
[5]	方圻,王钟林,宁田海,等. 脂异常防治对策专题组.血脂异常防治建议[ J ] .中华心血管病杂志,1997,26(3):10.
[6]	SMITH T,GILDEH N,HOLMES C.The montreal cognitive assessment:validity and utility in a memory clinic setting[J]. Can J Psychiatry,2007,52(5):329-332.
[7]	曾倩怡,杨青云,黎润仪. MoCA 和MMSE对稳定期精神分裂症认知功能障碍的评估应用[J].吉林医学,2013,34(14):2632-2634.
[8]	胡耀祖. 长期使用抗精神病药对精神分裂症患者认知功能的影响研究[J]. 中国药房,2012 ,23(2):168-170.
[9]	杨增云,张兰娥,卢国华,等.半胱氨酸血症与认知损害的关系研究[J].中国医药科学,2013,3(6):13-14.
[10]	朱祖欣,熊鹏,贾敏,等.首发精神分裂症患者的血清同型半胱氨酸水平及其与P300的关系[J].中国神经精神疾病杂志,2010,36(6):355-358.
[11]	孙晓,牛爱军,胡成进.同型半胱氨酸与精神分裂症的关系[J].中国医药导报,2013,10(27):28-30.
[12]	SHLAFMAN N,SHALDUBIN S,APPLEBAUM J,et al.No gross abnormality of plasma homocysteine after acute methionine loading in clinically stabilized patients with schizophrenia[J].Asian J Psychiatry,2010,3(2):64-66.
[13]	李钦云,张守字,王维山,等.血清总胆固醇和甘油三酯对认知功能影响的探讨[J].神经疾病与精神卫生,2011,11(3):245-247.
[14]	DE FRIAS CM,BUNCE D,WAHLIN A,et al.Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults[J]. J Gerontol B Psychol Sci Soc Sci,2007,62(2):P112-P118.
[15]	邵平,欧建军,吴仁容,等. 齐拉西酮与奥氮平对首发精神分裂症患者糖脂代谢的影响[J].中南大学学报:医学版,2013,38(4):365-369.
[16]	MEYER JS,RAUCH G,RAUCH RA,et al.Risk factors for cerebral hypoperfusion,mild cognitive impairment,and dementia[J].Neurobiol Aging,2000,21(2):161-169.

组别	例数	MoCA总分	年龄(岁)	病程(年)	Hcy(μmol/L)
认知障碍组	120	21.51±3.14^*#	54(27~60)	23.21±10.71	23.24±14.35^*#
无认知障碍组	34	26.56±0.66	53(26~60)	21.18±9.59	15.25±6.74
正常对照组	60	27.72±0.94	54(28~60)	-	12.68±2.02
组别	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)
认知障碍组	4.93±1.22^*#	2.25±1.83^*#	1.15±0.28^*	3.56±1.19^*#
无认知障碍组	4.39±0.96	1.37±0.76	1.24±0.36	3.10±0.92
正常对照组	4.20±0.71	1.29±0.28	1.35±0.26	3.03±0.81

组别	例数	MoCA总分	年龄(岁)	病程(年)	Hcy(μmol/L)
认知障碍组	120	21.51±3.14^*#	54(27~60)	23.21±10.71	23.24±14.35^*#
无认知障碍组	34	26.56±0.66	53(26~60)	21.18±9.59	15.25±6.74
正常对照组	60	27.72±0.94	54(28~60)	-	12.68±2.02
组别	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)
认知障碍组	4.93±1.22^*#	2.25±1.83^*#	1.15±0.28^*	3.56±1.19^*#
无认知障碍组	4.39±0.96	1.37±0.76	1.24±0.36	3.10±0.92
正常对照组	4.20±0.71	1.29±0.28	1.35±0.26	3.03±0.81

指标	认知障碍组		无认知障碍组		OR值	95%CI
指标	例数	阳性例数			OR值		例数	阳性例数
Hcy	120	87	34	13	0.005	1.114	1.034~1.200
TC	120	33	34	5	0.002	1.791	1.237~2.593
TG	120	66	34	9	0.005	2.141	1.263~3.630
LDL-C	120	53	34	12	0.015	1.556	1.091~2.217
HDL-C	120	23	34	3	0.150	0.415	0.126~1.373

指标	认知障碍组		无认知障碍组		OR值	95%CI
指标	例数	阳性例数			OR值		例数	阳性例数
Hcy	120	87	34	13	0.005	1.114	1.034~1.200
TC	120	33	34	5	0.002	1.791	1.237~2.593
TG	120	66	34	9	0.005	2.141	1.263~3.630
LDL-C	120	53	34	12	0.015	1.556	1.091~2.217
HDL-C	120	23	34	3	0.150	0.415	0.126~1.373

组别	例数	视空间与执行功能	命名	记忆力
高Hcy组	100	2.84±1.01^*	2.87±0.34	3.05±1.37
Hcy正常组	54	3.72±1.05	2.91±0.35	3.43±1.16
组别	注意力	语言表达	抽象能力	定向力
高Hcy组	3.78±1.07^*	0.96±0.71	0.80±0.79	5.53±0.69
Hcy正常组	4.85±0.90	1.02±0.72	1.00±0.93	5.67±0.51